BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell-driven cytolytic activity against prostate cancer.

Automated summary

Targeting PSMA with AMG 160 shows promising preclinical efficacy in inducing T cell-driven cytolytic activity against prostate cancer, highlighting its potential therapeutic implications in immune oncology.